MARKET

ENTA

ENTA

Enanta Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.30
+1.30
+2.32%
Closed 16:02 09/27 EDT
OPEN
56.32
PREV CLOSE
56.00
HIGH
57.82
LOW
55.78
VOLUME
80.16K
TURNOVER
--
52 WEEK HIGH
59.23
52 WEEK LOW
40.32
MARKET CAP
1.16B
P/E (TTM)
-13.7787
1D
5D
1M
3M
1Y
5Y
FOCUS-COVID-19 pill developers aim to top Merck, Pfizer efforts
reuters.com · 37m ago
SVB Leerink Initiates Coverage On Enanta Pharmaceuticals with Market Perform Rating, Announces Price Target of $55
SVB Leerink analyst Roanna Ruiz initiates coverage on Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Perform rating and announces Price Target of $55.
Benzinga · 09/09 10:28
Enanta Pharmaceuticals to Participate in Investor Conferences in September
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will par...
Business Wire · 09/07 11:00
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 12:19
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/31 12:05
BRIEF-Enanta Pharmaceuticals Elects Yujiro S. Hata To Its Board Of Directors
reuters.com · 08/23 12:40
Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
WATERTOWN, Mass., August 23, 2021--Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
Business Wire · 08/23 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENTA. Analyze the recent business situations of Enanta Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

11.11%Strong Buy
33.33%Buy
44.44%Hold
11.11%Under-perform
0.00%Sell
Analyst Price Target
The average ENTA stock price target is 65.33 with a high estimate of 107.00 and a low estimate of 35.00.
High107.00
Average65.33
Low35.00
Current 57.30
EPS
Actual
Estimate
-1.17-0.88-0.58-0.29
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 241
Institutional Holdings: 19.55M
% Owned: 96.73%
Shares Outstanding: 20.21M
TypeInstitutionsShares
Increased
47
844.97K
New
18
241.76K
Decreased
58
1.31M
Sold Out
16
358.21K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.10%
Pharmaceuticals & Medical Research
-0.86%
Key Executives
Non-Executive Chairman/Independent Director
Bruce Carter
President/Chief Executive Officer/Director
Jay Luly
Chief Financial Officer/Senior Vice President - Finance
Paul Mellett
Senior Vice President/Chief Scientific Officer
Yat Sun Or
Senior Vice President/General Counsel
Nathaniel Gardiner
Senior Vice President
Nathalie Adda
Senior Vice President
Tara Kieffer
Senior Vice President
Brendan Luu
Independent Director
Mark Foletta
Independent Director
Yujiro Hata
Independent Director
Kristine Peterson
Independent Director
Lesley Russell
Independent Director
Terry Vance
No Data
About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company uses chemistry-driven approach and drug discovery capabilities. The Company is focused on discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). It also conducts research in human metapneumovirus (hMPV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease-2019 (COVID-19). The Company has discovered glecaprevir, a protease inhibitor discovered and developed through its collaboration with AbbVie for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie’s direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET.

Webull offers kinds of Enanta Pharmaceuticals Inc stock information, including NASDAQ:ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.